Wed, March 25, 2026 at 2:58 PM UTC Here is a fact that should reframe how you think about Insmed (NASDAQ:INSM) and its lung disease franchise: Japan has more patients with MAC lung disease than the ...

Insmed (INSM) announced positive Phase 3b results for ARIKAYCE as first-line MAC lung disease therapy, potentially expanding its addressable market from 30,000 to over 200,000 patients, with a ...

"These results are an exciting win for patients living with MAC lung disease and a powerful validation of ARIKAYCE's ability to deliver real clinical benefit as part of a multidrug treatment regimen," ...

Insmed Incorporated, a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, announced ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

In March 2026, Insmed reported positive Phase 3b ENCORE results showing ARIKAYCE added to standard multidrug therapy improved symptoms and culture conversion in patients with MAC lung disease who were ...

—The Study Met Primary and All Multiplicity-Controlled Secondary Culture Conversion Endpoints, Demonstrating Statistically Significant and Clinically Meaningful Improvements in Respiratory Symptom ...

Shares of Insmed climbed after the company disclosed what it called positive topline results from a late-stage study of its treatment for certain lung infections. The stock rose 10%, to $150.02, in ...

ESCMID is the premier annual congress of the European Society of Clinical Microbiology and Infectious Diseases. It takes place from April 17 - 21, 2026 in Munich, Germany.

A public health expert who contributed to a study on indoor air pollution says switching to cleaner fuels may be a matter of ...